|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
154,660,000 |
Market
Cap: |
156.21(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.429 - $1.75 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Adaptimmune Therapeutics is a biopharmaceutical company focused on developing T-cell therapies for solid tumors. Co.'s proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors against those targets, and produce therapeutic candidates (SPEAR T-cells) for administration to patients. Co. has clinical trials on its ADP-A2M4, ADP-A2M4CD8, each targeting the MAGE-A4 antigen, and ADP-A2AFP SPEAR T-cells targeting the alpha fetoprotein (AFP) cancer antigen in solid tumor types including non-small cell lung cancer, head and neck cancer, ovarian, urothelial, melanoma, and hepatocellular.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
165,799 |
218,930 |
354,372 |
Total Sell Value |
$0 |
$124,385 |
$172,782 |
$411,912 |
Total People Sold |
0 |
4 |
5 |
6 |
Total Sell Transactions |
0 |
16 |
19 |
41 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Ecor1 Capital, Llc |
10% Owner |
|
2024-03-08 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
164,424,420 |
|
-41% |
|
Norry Elliot |
Chief Medical Officer |
|
2024-01-17 |
4 |
S |
$0.67 |
$12,300 |
D/D |
(18,276) |
19,257 |
|
-43% |
|
Lunger John |
Chief Patient Supply Officer |
|
2024-01-17 |
4 |
S |
$0.67 |
$12,191 |
D/D |
(18,114) |
19,015 |
|
-43% |
|
Bertrand William C Jr |
Chief Operating Officer |
|
2024-01-17 |
4 |
S |
$0.67 |
$12,725 |
D/D |
(18,908) |
20,201 |
|
-43% |
|
Rawcliffe Adrian |
Chief Executive Officer |
|
2024-01-17 |
4 |
S |
$0.67 |
$20,244 |
D/D |
(30,080) |
44,848 |
|
-43% |
|
Norry Elliot |
Chief Medical Officer |
|
2024-01-16 |
4 |
S |
$0.79 |
$1,807 |
D/D |
(2,287) |
3,363 |
|
-48% |
|
Lunger John |
Chief Patient Supply Officer |
|
2024-01-16 |
4 |
S |
$0.79 |
$3,698 |
D/D |
(4,681) |
7,023 |
|
-48% |
|
Bertrand William C Jr |
Chief Operating Officer |
|
2024-01-16 |
4 |
S |
$0.79 |
$3,698 |
D/D |
(4,681) |
7,023 |
|
-48% |
|
Rawcliffe Adrian |
Chief Executive Officer |
|
2024-01-16 |
4 |
S |
$0.79 |
$7,350 |
D/D |
(9,304) |
14,104 |
|
-48% |
|
Lunger John |
Chief Patient Supply Officer |
|
2024-01-12 |
4 |
S |
$0.85 |
$4,458 |
D/D |
(5,220) |
7,874 |
|
-23% |
|
Bertrand William C Jr |
Chief Operating Officer |
|
2024-01-12 |
4 |
S |
$0.85 |
$4,458 |
D/D |
(5,220) |
7,874 |
|
-23% |
|
Rawcliffe Adrian |
Chief Executive Officer |
|
2024-01-12 |
4 |
S |
$0.85 |
$14,739 |
D/D |
(17,257) |
26,388 |
|
-23% |
|
Norry Elliot |
Chief Medical Officer |
|
2024-01-12 |
4 |
S |
$0.85 |
$6,661 |
D/D |
(7,799) |
11,841 |
|
-23% |
|
Lunger John |
Chief Patient Supply Officer |
|
2024-01-11 |
4 |
S |
$0.84 |
$3,354 |
D/D |
(4,009) |
6,104 |
|
-19% |
|
Bertrand William C Jr |
Chief Operating Officer |
|
2024-01-11 |
4 |
S |
$0.84 |
$3,354 |
D/D |
(4,009) |
6,104 |
|
-19% |
|
Rawcliffe Adrian |
Chief Executive Officer |
|
2024-01-11 |
4 |
S |
$0.84 |
$9,994 |
D/D |
(11,945) |
18,395 |
|
-19% |
|
Norry Elliot |
Chief Medical Officer |
|
2024-01-11 |
4 |
S |
$0.84 |
$3,354 |
D/D |
(4,009) |
6,104 |
|
-19% |
|
Lunger John |
Chief Patient Supply Officer |
|
2023-08-01 |
4 |
S |
$0.91 |
$2,804 |
D/D |
(3,096) |
4,718 |
|
37% |
|
Menzel Garry E |
Director |
|
2023-07-10 |
4 |
S |
$0.91 |
$43,447 |
D/D |
(47,702) |
75,056 |
|
47% |
|
Rawcliffe Adrian |
Chief Executive Officer |
|
2023-06-27 |
4 |
S |
$0.92 |
$2,146 |
D/D |
(2,333) |
3,519 |
|
39% |
|
Menzel Garry E |
Director |
|
2023-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
209,931 |
209,931 |
|
- |
|
Menzel Garry E |
Director |
|
2023-06-01 |
4 |
A |
$0.00 |
$0 |
I/I |
401,293 |
200,647 |
|
- |
|
Piccina Cintia |
Chief Commercial Officer |
|
2023-01-31 |
4 |
S |
$1.87 |
$22,230 |
D/D |
(11,890) |
19,535 |
|
47% |
|
Lunger John |
Chief Patient Supply Officer |
|
2023-01-17 |
4 |
S |
$1.86 |
$8,250 |
D/D |
(4,440) |
7,264 |
|
33% |
|
Bertrand William C Jr |
Chief Operating Officer |
|
2023-01-17 |
4 |
S |
$1.86 |
$8,250 |
D/D |
(4,440) |
7,264 |
|
33% |
|
234 Records found
|
|
Page 1 of 10 |
|
|